^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    UGT1A1 mutation

    i
    Other names: UGT1A1, UDP glucuronosyltransferase family 1 member A1, GNT1, UGT1, UDPGT, UGT1A, HUG-BR1, BILIQTL1, UDPGT 1-1
    Entrez ID:
    54658
    Related biomarkers:
    Mutation
    over1year
    HOVON150AML: A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (clinicaltrials.gov)
    P3, N=968, Active, not recruiting, Stichting Hemato-Oncologie voor Volwassenen Nederland | Recruiting --> Active, not recruiting | Trial completion date: May 2034 --> Sep 2034 | Trial primary completion date: Oct 2024 --> Apr 2027
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy
    |
    FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    IDH1 mutation • IDH2 mutation • FLT3 mutation • IDH1 R132 • UGT1A1*1*1 • FLT3 mutation + IDH1 mutation • IDH2 R140 • IDH2 R172 • UGT1A1 mutation
    |
    Tibsovo (ivosidenib) • Idhifa (enasidenib)
    almost2years
    A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (clinicaltrials.gov)
    P1/2, N=60, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Sep 2027 --> Sep 2025
    Trial completion date • Combination therapy
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    UGT1A1*1*1 • UGT1A1 mutation
    |
    Rituxan (rituximab) • lenalidomide • Ezharmia (valemetostat)
    almost2years
    IDHENTIFY: An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (clinicaltrials.gov)
    P3; Active, not recruiting --> Completed
    Trial completion
    |
    IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation
    |
    Abbott RealTime IDH2
    |
    cytarabine • azacitidine • Idhifa (enasidenib) • hydroxyurea
    almost2years
    A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients (clinicaltrials.gov)
    P1, N=40, Completed, Celgene | Active, not recruiting --> Completed
    Trial completion
    |
    IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation
    |
    Idhifa (enasidenib) • midazolam hydrochloride • omeprazole
    almost2years
    IDHENTIFY: An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (clinicaltrials.gov)
    P3; Trial completion date: Dec 2023 --> Mar 2024
    Trial completion date
    |
    IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation
    |
    Abbott RealTime IDH2
    |
    cytarabine • azacitidine • Idhifa (enasidenib) • hydroxyurea
    almost2years
    AG-221-C-001: Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation (clinicaltrials.gov)
    P1/2, N=345, Completed, Celgene | Active, not recruiting --> Completed
    Trial completion
    |
    IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    IDH2 mutation • UGT1A1*1*1 • Chr t(15;17) • UGT1A1 mutation
    |
    Idhifa (enasidenib)
    2years
    A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma (clinicaltrials.gov)
    P2, N=1, Terminated, Hackensack Meridian Health | N=43 --> 1 | Trial completion date: May 2026 --> Nov 2023 | Recruiting --> Terminated | Trial primary completion date: May 2025 --> Nov 2023; Low Accrual
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    UGT1A1*1*1 • UGT1A1 mutation
    |
    Darzalex (daratumumab) • pomalidomide
    2years
    Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer (clinicaltrials.gov)
    P1; Phase classification: P1b --> P1
    Phase classification
    |
    HER-2 (Human epidermal growth factor receptor 2) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    UGT1A1*1*1 • UGT1A1 mutation
    |
    PATHWAY antiHer2/neu (4B5) Rabbit Monoclonal Primary Antibody
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • Ezharmia (valemetostat)
    2years
    Genetic variations underlying Gilbert syndrome and HBV infection outcomes: a cross-sectional study. (PubMed, Front Genet)
    We showed that the accumulation of UGT1A1 variants or the rarity of the variation is associated with a better prognosis, and the effect magnitude correlates with UGT1A1 deficiency. This study demonstrates the therapeutic potential of host UGT1A1 variations underlying GS against HBV infection outcomes.
    Observational data • Journal
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    UGT1A1*28 • UGT1A1*1*1 • UGT1A1 mutation • UGT1A1 wild-type
    over2years
    AG120-221-C-001: Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation (clinicaltrials.gov)
    P1, N=153, Active, not recruiting, Institut de Recherches Internationales Servier | Trial completion date: Jul 2023 --> Jul 2024
    Trial completion date • Combination therapy
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    IDH2 mutation • UGT1A1*1*1 • Chr t(15;17) • UGT1A1 mutation
    |
    cytarabine • etoposide IV • Tibsovo (ivosidenib) • daunorubicin • Idhifa (enasidenib) • idarubicin hydrochloride • mitoxantrone
    over2years
    Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRC (clinicaltrials.gov)
    P2, N=92, Recruiting, Fudan University
    New P2 trial • Surgery
    |
    BRAF (B-raf proto-oncogene) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    BRAF mutation • RAS mutation • UGT1A1*28 • UGT1A1*1*1 • UGT1A1 mutation
    |
    5-fluorouracil • oxaliplatin • irinotecan • Fruzaqla (fruquintinib) • leucovorin calcium
    over2years
    Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer (clinicaltrials.gov)
    P2, N=50, Recruiting, Fudan University
    New P2 trial • Metastases
    |
    BRAF (B-raf proto-oncogene) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    BRAF mutation • RAS mutation • UGT1A1*28 • UGT1A1*1*1 • UGT1A1 mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • leucovorin calcium